Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

New Jersey Scientists Developing Unique Antibiotic to Treat Deadly MRSA

10/14/2016

0 Comments

 
Montclair, NJ — Lilo H. Stainton reports in NJ Spotlight that the discovery of antibiotics nearly a century ago is heralded as one of the great advances in modern medicine.
 
But these wonder drugs have become less effective over time, and tens of thousands of Americans now die every year when physicians run out of ways to ward off deadly infections.
 
Pharmaceutical companies are now responding, and at least three-dozen new antibiotics are now under development nationwide, experts said. A team of researchers in New Jersey is one of the leaders in this effort, and its work on a novel approach could be ready for patients by 2020.
 
Based on technology created by Rutgers scientists and developed with help from TAXIS Pharmaceuticals, a drug maker in Monmouth Junction, TXA709 is specifically designed to treat MRSA, an extremely deadly bacterial infection that doesn’t respond to existing antibiotics.
 
The Federal Drug Administration has now given the team approval to test the drug on animals, and they hope to follow with human trials in the spring.
 
TXA709 was developed by Daniel Pilch, an associate professor in the pharmacology department at Robert Wood Johnson Medical School, and Edmond LaVoie, a professor and chair of the medicinal chemistry department at Rutgers’ pharmacy school, explained Yair Harel, the executive director for New Ventures at Rutgers.
​Rutgers holds the license. The school partnered with TAXIS as part of a standard process to continue trials, research, and other aspects of commercialization, Harel said. Pilch and LaVoie helped form the company in 2009.
 
MRSA, or methicillin-resistant Staphylococcus aureus, kills some 19,000 Americans and adds $3 billion to the country’s annual healthcare costs, according to the Rutgers research team’s announcement last spring.
 
Advocates gathered this past weekend in Chicago to mark World MRSA Day on Sunday, October 2 — an event first designated in 2009.
 
Their efforts may be having an effect. Infection rates have been declining in recent years nationwide, including in New Jersey.
 
 But reports of MRSA at Garden State hospitals were roughly five percent higher than the national average, according to data from the federal Centers for Disease Control and Prevention.
 
While it is not limited to healthcare facilities, most infections show up in hospitals, rehab, or nursing homes among patients who have compromised immune systems.
 
The underlying problem for MRSA, and other diseases resistant to antibiotics, is that as these life-saving drugs became more common, the ever-evolving bacteria grew in new ways that enabled them to resist the force of whatever medicine was once a cure.
 
And as pharmaceutical companies migrated away from developing new antibiotics, focusing instead on better-paying sectors like cancer drugs, resistant infections flourished in recent decades.
 
A growing awareness of the problem among healthcare providers, researchers, and public leaders has started to reverse this trend.  
 
Those in the pharmaceutical industry also credit the 2011 federal GAIN Act, or Generating Antibiotic Incentives Now, which offered patent advantages and other benefits to companies that ventured back into antibiotics.
 
TXA709 is one of those products to benefit from this law, but the Monmouth Junction company is not alone.
 
Debbie Hart, president and CEO of BioNJ, an advocacy group for the state’s biotech industry, said there are a number of Garden State companies working on new antibiotics and some 37 products in the pipeline nationwide.  Economic incentives and other policy changes have helped spark this revival.
 
“There is a perfect storm right now given the combination of the need, the advances in the science, such as that underway at TAXIS, and the increase in incentives and potential incentives,” Hart said, “that is resulting in increased research in this important area.”
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507